The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or Amidated Dopamine Neuron Stimulating peptides (ADNS peptides) ), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies
